The CAPTAIN trial compared the MRI-Guided TULSA Procedure™ to robotic radical prostatectomy for localized prostate cancer.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...
Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...
Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) procedure on the East Coast using the Vanquish(R) ...
Men with prostate cancer have a major decision to make: whether to get a lifesaving surgery. Radical prostatectomy, the ...
Mordor Intelligence has published a new report on the prostate cancer market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results